Related Experiment Video
Updated: Jul 13, 2026
17:42
A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation
Published on: April 13, 2011
Islet transplantation in treating diabetes.
Annual Review of Medicine
|January 1, 1986
Summary
Pancreatic islet transplantation shows promise for reversing diabetes and its complications. Recent advancements enable successful transplantation without long-term immunosuppression, paving the way for human clinical trials.
Area of Science:
- Endocrinology and Metabolic Diseases
- Transplantation Immunology
- Regenerative Medicine
Background:
- Pancreatic islet transplantation is a potential cure for type 1 diabetes.
- Previous challenges included graft rejection and the need for continuous immunosuppression.
- Experimental success in animals demonstrated potential for reversing diabetes and complications.
Purpose of the Study:
- To evaluate the feasibility of pancreatic islet transplantation in humans.
- To assess novel methods for islet isolation and transplantation.
- To overcome barriers to successful islet engraftment and long-term function.
Main Methods:
- Development of methods to prevent rejection of allogeneic islets in rodents without chronic immunosuppression.
- Establishment of a new protocol for isolating a significant yield (40%) of islets from a single human pancreas.
- Initiation of the first phase of human clinical trials for islet transplantation.
Main Results:
- Successful reversal of diabetes in experimental animal models.
- Prevention or reversal of early diabetic complications in transplanted recipients.
- Successful isolation of a high yield of islets from human pancreases, enabling clinical trials.
Conclusions:
- Pancreatic islet transplantation has reached a critical stage, nearing widespread clinical application.
- Advances in immunosuppression strategies and islet isolation techniques are key to successful human trials.
- The initiation of human clinical trials marks a significant milestone in the quest to cure diabetes through islet transplantation.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...